News & Current Events
- Merck KGaA Signs $550 Million Cancer Pact With Threshold Pharmaceuticals, Inc.
- DARMSTADT, Germany, Feb 03, 2012 (BUSINESS WIRE) -- --Deal provides Threshold with an upfront payment of EUR 19 million ($25 million), plus further potential milestones and royalties as well as an option to co-commercialize in the United States
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc...
- Idenix Pharmaceuticals, Inc. Receives FDA Notification That Partial Clinical Hold on IDX184 Removed
- CAMBRIDGE, Mass., Feb. 3, 2012 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has received notification from the U.S. Food and Drug Administration (FDA) that the partial clinical hold on IDX184 has been removed...
- Q&A About $100 Million Asia, Emerging Markets Strategy With AstraZeneca PLC's Head of R&D
- The health challenges of China and Asia offer big opportunities for multinational pharma companies. Cases of chronic diseases, such as diabetes, are on the rise in the region, as are lung, gastric, and liver cancers. China alone is likely to be the worlds third-largest pharmaceutical market by this year, with sales of more than $50 billion. AstraZeneca, the largest multinational pharmaceutical company...
- Merrimack Pharmaceuticals Inc. Scraps IPO Plans
- Boston Business Journal by Julie M. Donnelly, Reporter
Merrimack Pharmaceuticals has postponed its $166 million IPO, originally scheduled for this week, according to IPO tracker Renaissance Capital, due to poor market conditions.
The Cambridge, Mass-based company, which is developing potential treatments for cancer, planned to sell 16,666,667 shares of common stock at an estimated...
- Discovery Laboratories Gets FDA OK for Aerosol Medicines Delivery System
- WARRINGTON, Pa., Feb. 2, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient...
- Athersys, Inc. Announces Positive Results of MultiStem(R) Clinical Trial for Hematopoietic Stem Cell Transplant Support and Prevention of Graft-Versus-Host Disease
- CLEVELAND, Feb. 1, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX - News) today announced positive results from its Phase I clinical trial of MultiStem(R), its cell therapy product, administered to individuals undergoing allogeneic hematopoietic stem cell transplants (HSCT) for the treatment of leukemia and related conditions. According to the Center for International Blood and Marrow Transplant...
- Drugmakers Including GlaxoSmithKline Scuttle Plan for Approval System Pushed by Biotechs
- Drugmakers including GlaxoSmithKline Plc have fought off a U.S. senators proposal that would have approved medicines for diseases that are fatal, or have no existing treatments, based on fewer human trials. The plan, drafted by Democratic Senator Kay Hagan of North Carolina, was being pushed by biotechnology companies to speed up approvals and make the process less expensive. It would have created...
- Ligand Pharmaceuticals Inc. Presents Full Data from Successful Phase II Trial of Captisol-Enabled??, Propylene Glycol-Free Melphalan at the BMT Tandem Meetings
- SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND - News) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood...
- Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd.'s Bowel Dysfunction Drug Succeeds in Second Phase III Study
- BETHESDA, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Patients received lubiprostone...
- Valeant Pharmaceuticals International Acquires in Brazil for $85 Million
- MISSISSAUGA, Ontario, Feb. 1, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that Valeant has acquired Probiotica Laboratorios Ltda., a leader in sports nutrition and food supplements in Brazil. Probiotica currently markets a full line of over-the-counter sports nutrition products and other food supplements, with a 30 percent share...
- Sangamo BioSciences, Inc. to Partner With Shire plc for $13 Million to Develop DNA Technology
- DUBLIN and RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for...
- Female Frontrunners in Biotech
- Excelling in industry is not easy, especially if youre a woman. According to a 2010 study of New England biotech firms, females comprised only about 12 percent of biotech founders, despite earning about half of the biological science PhDs. And women are equally underrepresented at the senior management level, holding just 12 percent of senior executive positions in the worlds top drug companies and...
- Impax Pharmaceuticals Gains Rights for US Sales of AstraZeneca PLC's Zomig; Paying $130 Million in 2012
- HAYWARD, Calif.--(BUSINESS WIRE)-- Impax Pharmaceuticals, the branded products business unit of Impax Laboratories, Inc. (NASDAQ: IPXL - News), announced today that it has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations. As part of a Distribution, License, Development and Supply...
- FDA Approves Boehringer Ingelheim Corporation, Eli Lilly and Company's Diabetics Therapy Jentadueto???
- RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ --Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new...
- FDA Approves Vertex Pharmaceuticals Incorporated's Cystic Fibrosis Drug
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved KALYDECOTM (ivacaftor), the first medicine to treat the underlying cause of cystic fibrosis (CF), a rare, genetic disease. KALYDECO (kuh-LYE-deh-koh) is approved for people with CF ages 6 and older who have at least one copy of the G55...
- Savient Pharmaceuticals, Inc. Appoints Interim Chief Executive Officer
- EAST BRUNSWICK, N.J., Feb. 1, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company's Board of Directors has appointed David Y. Norton, a member of the Savient Board and former Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, to the role of Interim Chief Executive...
- Ablynx Receives Another EUR $5 Million Milestone as Boehringer Ingelheim Corporation Selects Nanobody Candidate for Pre-Clinical Development
- SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--MEDIAN Technologies (Paris:ALMDT)(ALMDT), a leading services provider for image interpretation and management in oncology clinical trials, and software provider for medical imaging, announced today the signature of a landmark contract with the top pharmaceutical company SANOFI for the interpretation and end-to-end management of medical images in a phase II...
- Transparency Life Sciences, LLC Launched as World's First Drug Development Company Based on Open Innovation
- New York, NY and Philadelphia, PA - January 31, 2012 - Transparency Life Sciences, LLC (TLS) the worlds first drug development company based on open innovation, announced its official launch today with the introduction of a prototype of the companys crowdsourced web platform that allows patients, physicians, researchers and other stakeholders to contribute to the design of clinical studies. The...
- BioSante Pharmaceuticals, Inc. Cuts 25% of Workforce
- LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced a corporate update.
Corporate development: In light of the recently announced top-line results from BioSantes two pivotal Phase III LibiGel (testosterone gel) efficacy trials, BioSante is evaluating its corporate strategy. BioSante continues to investigate alternative strategies to utilize...
- Orexo AB, Janssen Pharmaceutical K.K. Axe Preclinical-Stage Deal in Respiratory Diseases
- UPPSALA, Sweden--(BUSINESS WIRE)-- Regulatory News: Orexo AB (STO:ORX.ST - News) and Janssen Pharmaceuticals, Inc., formerly Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica NV ("Janssen"), have decided to end their research collaboration and license agreement regarding the OX-CLI and OX-ESI programs and a third, undisclosed Janssen program. Each party has regained all commercial...
- Tech Council of Maryland Appoints as Interim CEO
ROCKVILLE, MD--(Marketwire - January 30, 2012) - The Tech Council of Maryland (TCM), Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art...
- Teva Pharmaceutical Industries Limited's Cephalon, Inc. Recalls Treanda Leukemia Drug Due to Glass Fragments
- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) US subsidiary Cephalon has recalled a lot of its Treanda leukemia drug, because glass fragments were found in one of the vials. The US Food and Drug Administration (FDA) said in a statement that Cephalon distributed the Treanda lot TB30111 to wholesalers and distributors between March 22 and October 5, 2011, and notified those recipients...
- GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc. Said to be Interested in Turkey's
- GlaxoSmithKline Plc (GSK), Eli Lilly & Co. and Pfizer Inc. (PFE) are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said. The owners of Mustafa Nevzat, or MN Pharmaceuticals as the Istanbul-based company is known, have hired Bank of America Merrill...
- FDA Approves Amylin Pharmaceuticals, Inc. and Alkermes plc's BYDUREON??? -- The First and Only Once-Weekly Treatment for Type 2 Diabetes
- SAN DIEGO and DUBLIN, Jan. 27, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved BYDUREON (exenatide extended-release for injectable suspension) the first once-weekly treatment for type 2 diabetes. BYDUREON...
- Teva Pharmaceutical Industries Limited Eyes $2 Billion Micro Laboratories, Inc. Acquisition
- The fact that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has explicitly said that it has no plans to make large acquisitions any time soon has not stopped speculations about the company's next buyout. Indian website "VCCircle" reports that Teva is a contender to acquire Micro Labs Ltd. for almost $2 billion. While the amount is not on the scale of Teva's last three multibillion...
- Drugmakers Including GlaxoSmithKline and Sanofi (France) Join $785 Million Tropical-Disease Fight
- LONDON, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.
Uniting efforts with NTD...
- Bayer AG Gets Approval for Gadovist For Children Aged 2-6 Years
- German pharmaceutical company Bayer AG (BAYN.XE) said Friday it got approval for use of Gadovist 1.0 in children aged two to six years in the Europe Union. Gadovist is a contrast medium, which is injected to make diseases visible in magnetic resonance tomography examinations, an imaging technique. It is approved for the most frequently conducted contrast enhanced magnetic resonance tomography examinations...
- Valeant Pharmaceuticals International Withdraws Bid for ISTA Pharmaceuticals, Inc.
- MISSISSAUGA, Ontario, Jan. 30, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has withdrawn its offer to acquire ISTA Pharmaceuticals Inc. (Nasdaq: ISTA) for $7.50 per share in cash. Valeant had previously announced that the offer would only remain open until
- Lannett Company, Inc. Receives FDA Approval for Hydrochlorothiazide Capsules, 12.5 mg
- PHILADELPHIA--(BUSINESS WIRE)-- Lannett Company, Inc. (NYSE AMEX: LCI) today announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Hydrochlorothiazide Capsules, 12.5 mg. Hydrochlorothiazide Capsules, 12.5 mg, is therapeutically equivalent to the reference listed drug, MicrozideCapsules, 12.5 mg, of Watson Pharmaceuticals...
- Antitrust: Commission Closes Procedural Case Against Servier
- (NewDesignWorld Press Center) - Brussels - The Commission has closed an investigation into Les Laboratoires Servier for suspected provision of misleading and incorrect information to the Commission's pharmaceuticals sector inquiry.
In 2010, the Commission addressed statements of objections to Les Laboratoires Servier and Servier SAS, a French pharmaceutical company, taking the provisional...
- Infinity Pharmaceuticals Inc. Halts Phase II Cancer Drug Trial
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced interim data from its double-blind, randomized, placebo-controlled Phase 2 study comparing saridegib (also known as IPI-926) in combination with gemcitabine to placebo plus gemcitabine in 122 patients with previously untreated, metastatic pancreatic cancer. The primary endpoint of the Phase 2 study is overall...
- The Hotbed Driving Force in Biotech: Massachusetts
By Michelle Wong, BioSpace.com
Massachusetts is picking up steam in the biotech industry while...- Pfizer Inc. Sued by Employees Over Retirement Plans
- Employees of Pfizer Inc. have filed suit against the company, alleging the world's largest drug maker failed to properly manage its retirement plans and caused losses totaling hundreds of millions over the past decade in one of the hubs of the pharmaceutical industry. The suit, filed Wednesday in federal court in Puerto Rico, alleges Pfizer allowed employees to amass such high concentrations of company...
- Verastem, Inc. Bucks the Trend, Raises $55 Million in IPO
- CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold...
Warning: session_start() [function.session-start]: Cannot send session cache limiter - headers already sent (output started at /home/techcncl/techcouncilmd.com/mdbio/news/index.php:29) in /home/techcncl/techcouncilmd.com/scripts/aifm0903conn32m.php on line 9
- NCKU to Collaborate with IBM Thomas J. Watson Research Center to Set up Taiwan’s Most Efficient Supercomputing Research Center
- TAINAN, Taiwan--(BUSINESS WIRE)--NCKU to collaborate with IBM Thomas J. Watson Research Center to set up Taiwan’s most efficient Supercomputing Research Center
- Fractal Antenna Takes Sound Wireless
- WALTHAM, Mass.--(BUSINESS WIRE)--Rock concerts and sporting events just got the pick-up they needed – the antenna pick-up that is. Live entertainment shows have long been plagued with awkwardly-shaped, low-performance antennas used for wireless microphones and lighting controls. The solution for integrators, until now, has been to build the stage, or the arena, with more and more eyesore antennas just to get satisfactory coverage and performance. Now, Fractal Antenna Systems, Inc. (FRACTAL), wit
- Research and Markets: An Opportunity Assessment & Outlook for the 2011 North America SMB Mobility Landscape: From horizontal to Line of Business (LOB) applications
- DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b9aa44/2011_north_america) has announced the addition of the "2011 North America SMB Mobility Landscape, Opportunity Assessment & Outlook" report to their offering. This study delivers insights on how the U. S. and Canada SMBs are adjusting and adapting to the ever increasing mobile environment. From horizontal applications such as productivity (spreadsheets, presentations) and UC (audio/web/video confe
- Microsoft Honors Perficient with Best Practices Award
- ST. LOUIS--(BUSINESS WIRE)--Perficient, Inc. received the “Best Practice Award” at Microsoft’s Southwest District bi-annual partner briefing for a SharePoint solution developed for a large automotive manufacturer.
- Selon l'indice Monster de l'emploi, l'activité de recrutement en ligne en Europe baisse séquentiellement mais enregistre une croissance annuelle de 9 %
- NEW YORK--(BUSINESS WIRE)--Monster Worldwide, Inc. (NYSE : MWW) : Faits marquants de l'indice de janvier 2012 : L'indice Monster de l'emploi en Europe affiche en janvier une croissance annuelle de 9 %, un taux qui contraste avec la croissance à deux chiffres observée durant 2011 L'Allemagne reste le seul pays à afficher une forte croissance annuelle, avec un taux de 30 % ; elle continue d'être en tête face à tous les autres pays en termes de croissance annuelle Les Pays-Bas, l'Italie, la Belgiqu
- SofTech Adopts Rights Agreement Designed to Preserve Use of NOLs
- LOWELL, Mass.--(BUSINESS WIRE)--SofTech, Inc. (OTCQB: SOFT), a proven provider of Product Lifecycle Management (PLM) solutions today announced that its Board of Directors has adopted a rights agreement (the “Rights Agreement”) designed to preserve the value of its federal net operating loss carryforwards (“NOLs”) from unintended limitation under Section 382 of the Internal Revenue Code (“Section 382”). As of May 31, 2011 SofTech had NOLs of approximately $18.3 million. NOLs can generally be used
- Auto Dealers Can Increase Daily Revenue by as Much as 30% by Using Marchex Call Analytics Technology
- SEATTLE--(BUSINESS WIRE)--Marchex, Inc. (NASDAQ:MCHX), today announced the results of a Marchex Institute analysis of emerging call advertising trends for the auto industry. This data has unveiled several opportunities for auto dealerships to dramatically improve sales. As a leading provider of call tracking and analytics to businesses, including auto dealers and marketers, Marchex helps its customers gain a deeper understanding of inbound customer phone calls to increase sales close rates and c
- Genzyme Corporation Hit With Layoffs as Sanofi (France) Integration Continues
- Genzyme Corp.s research and development operations in Massachusetts have been cut by an unspecified number of positions, according to parent company Sanofi (NYSE: SNY). The positions have been eliminated to avoid redundancy between Sanofi and Genzyme staff, and do not reflect cuts to any specific drug development programs, the firm said.
- Is Eli Lilly and Company???s Alzheimer???s Drug Its Ace in the Hole?
- A treatment for Alzheimer's disease is the drug industry's longest shot, and any brave investors willing to place a bet on the outcome are likely to focus on Eli Lilly & Co. Lilly and Pfizer Inc are the farthest along in developing experimental medicines for the memory-robbing disease. But Lilly, as the far smaller company, has much more upside for its share price if it hits pay dirt. The field is...
- Drugmakers Including GlaxoSmithKline Scuttle Plan for Approval System Pushed by Biotechs
- Drugmakers including GlaxoSmithKline Plc have fought off a U.S. senators proposal that would have approved medicines for diseases that are fatal, or have no existing treatments, based on fewer human trials. The plan, drafted by Democratic Senator Kay Hagan of North Carolina, was being pushed by biotechnology companies to speed up approvals and make the process less expensive. It would have created...
- GlaxoSmithKline Settles 20,000 Lawsuits Over Avandia, Lawyer Says
- GlaxoSmithKline Plc (GSK), which is paying $3 billion to resolve government claims that it illegally marketed drugs such as the Avandia diabetes medication, agreed to settle more lawsuits over the pills, a lawyer said. Glaxo, the U.K.s biggest drugmaker, agreed last month to resolve more than 20,000 cases alleging Avandia causes heart attacks, said Paul Kiesel, a lawyer for former users. The accord...
- Pfizer Inc. Recalls 1 Million Birth Control Packs After Mixup
- Pfizer Inc. is recalling 1 million packets of birth control pills because of a packaging error that could leave women with an inadequate dose of the hormone-based drugs and raise the risk that they will get pregnant accidentally. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in...
- Dendreon Corporation Taps Savient Pharmaceuticals, Inc.'s as CEO
- SEATTLE--(BUSINESS WIRE)--February 1, 2012 Dendreon Corporation (Nasdaq: DNDN) today announced that its Board of Directors has elected John H. Johnson to the position of president and chief executive officer (CEO), to succeed Mitchell H. Gold, MD, who has served as president and CEO for nearly a decade. Dr. Gold has been elected executive chairman and will serve in that role until June 30, 2012...
- Pfizer Inc., Eli Lilly and Company Profits Fall as Drugs Lose Patents
- Drug makers Pfizer Inc. and Eli Lilly & Co. were hurt by the "patent cliff," with each reporting declines in fourth-quarter profit due to new generic competition for top-selling drugs. Both companies also spoke cautiously about experimental Alzheimer's disease drugs they're developing separately, though investor enthusiasm has mounted in the off chance that one or both of the drugs will reach the market...
- FDA Approves Boehringer Ingelheim Corporation, Eli Lilly and Company's Diabetics Therapy Jentadueto???
- RIDGEFIELD, Conn., and INDIANAPOLIS, Jan. 30, 2012 /PRNewswire/ --Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new...
- AB Science Reports Positive Clinical Study Data: Masitinib Significantly Extends Overall Survival as Compared to Pfizer Inc.'s Sutent??in Gleevec??-resistant GIST
- PARIS--(BUSINESS WIRE)--Regulatory News: AB Science SA (Paris:AB) (NYSE Euronext - FR0010557264 - AB) today announced encouraging results from a phase 2 study with its investigational drug, masitinib, in Gleevec-resistant gastrointestinal stromal tumors (GIST). Masitinib significantly improved overall survival in patients with Gleevec-resistant gastrointestinal stromal tumors (GIST) as compared to...
- Ablynx Receives Another EUR $5 Million Milestone as Boehringer Ingelheim Corporation Selects Nanobody Candidate for Pre-Clinical Development
- SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--MEDIAN Technologies (Paris:ALMDT)(ALMDT), a leading services provider for image interpretation and management in oncology clinical trials, and software provider for medical imaging, announced today the signature of a landmark contract with the top pharmaceutical company SANOFI for the interpretation and end-to-end management of medical images in a phase II...
- Tech Council of Maryland Appoints as Interim CEO
ROCKVILLE, MD--(Marketwire - January 30, 2012) - The Tech Council of Maryland (TCM), Maryland's largest technology trade association with more than 400 biotechnology and technology members employing more than 200,000 in the region, today announced that Art...
- Eli Lilly and Company Profit Slumps on Schizophrenia Drug
- Eli Lilly & Co. reported fourth- quarter profit that beat analysts estimates as higher sales of its depression and diabetes medicines helped to counter a 44 percent plunge in revenue from the schizophrenia drug Zyprexa. Net income fell 27 percent to $858.2 million, or 77 cents a share, the Indianapolis-based company said today in a statement. Profit excluding certain items beat by 6 cents the average...
- GlaxoSmithKline, Eli Lilly and Company, Pfizer Inc. Said to be Interested in Turkey's
- GlaxoSmithKline Plc (GSK), Eli Lilly & Co. and Pfizer Inc. (PFE) are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said. The owners of Mustafa Nevzat, or MN Pharmaceuticals as the Istanbul-based company is known, have hired Bank of America Merrill...
- Pfizer Inc. to Seek OK for Long-Stalled Menopause Drug
- Pfizer Inc. is preparing to seek U.S. regulatory approval to sell a new menopause drug that could pose an alternative to the company's older hormone-replacement therapies, which have been tied to safety risks. However, repeated delays in developing the new drug, Aprela, have raised questions about its potential. Some analysts and doctors question whether regulators will approve it, and Aprela's market...
- FDA Approves Pfizer Inc.'s INLYTA?? (axitinib) for Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
- NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved INLYTA (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. The approval is based on data from the Phase 3 AXIS trial, which demonstrated that INLYTA significantly extended progression free...
- Drugmakers Including GlaxoSmithKline and Sanofi (France) Join $785 Million Tropical-Disease Fight
- LONDON, Jan. 30, 2012 /PRNewswire-USNewswire/ -- Today, 13 pharmaceutical companies, the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade.
Uniting efforts with NTD...
- GlaxoSmithKline Seeking Acquisition in Turkey
- GlaxoSmithKline Plc (GSK), the U.K.s largest drugmaker, is seeking an acquisition in Turkey as it struggles to become profitable in the country, Hurriyet said, citing the companys emerging markets president. Potential targets include producers of cardiovascular drugs or businesses with production facilities that would add value to Glaxos operations, Hurriyet cited Abbas Hussain as saying. Glaxo...
- KineMed, Inc. Announces Research Collaboration with Pfizer Inc. for the Advancement of Novel Approaches in Metabolic Disease
- EMERYVILLE, Calif.--(BUSINESS WIRE)-- KineMed, Inc. (www.kinemed.com) today announced a non-exclusive research collaboration with Pfizer Inc. (NYSE:PFE - News) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMeds Dynamic ProteomicsTM technology platform to map the impact of potential drug candidates on specific metabolic...
- Pfizer Inc. Sued by Employees Over Retirement Plans
- Employees of Pfizer Inc. have filed suit against the company, alleging the world's largest drug maker failed to properly manage its retirement plans and caused losses totaling hundreds of millions over the past decade in one of the hubs of the pharmaceutical industry. The suit, filed Wednesday in federal court in Puerto Rico, alleges Pfizer allowed employees to amass such high concentrations of company...
- America's Oldest Companies
- IBM and Tiffany turned recently turned 100. But, if you think they're old, check out these companies. Some are older than the nation itself.
- Defective Birth Control Could Spur Big Lawsuits for Pfizer
- Women who become pregnant after taking the defective birth control pills Pfizer recalled today could sue the company for unwanted pregnancies.
Warning: DOMDocument::load(http://www.lifetechnologies.com/content/lifetech/en/home/rss/press-releases.rss) [domdocument.load]: failed to open stream: HTTP request failed! HTTP/1.0 404 Not Found in /home/techcncl/techcouncilmd.com/mdbio/news/index.php on line 178
Warning: DOMDocument::load() [domdocument.load]: I/O warning : failed to load external entity "http://www.lifetechnologies.com/content/lifetech/en/home/rss/press-releases.rss" in /home/techcncl/techcouncilmd.com/mdbio/news/index.php on line 178
- 14th Annual BIO CEO & Investor Conference to Highlight 2012 Investment Outlook, New Business Models and Key Therapeutic Topics
- WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference.
- BIO Urges Congress to Promptly Reauthorize PDUFA to Promote the Development of Innovative Therapies and Speed New Medicines to Patients
- WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the transmission of the Prescription Drug User Fee Act (PDUFA) V recommendations by the Secretary of Health and Human Services to Congress today: “Since PDUFA was enacted in 1992, it has contributed to the approval of more than 1,200 new medicines and initially reduced review times for the newest, most innovative drugs by more than a year. BIO strongly suppor
Follow
MdBio
